Puma Biotech (PBYI) Tops Q3 EPS by 13c, Misses on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mail
Get Alerts PBYI Hot Sheet
Join SI Premium – FREE
Puma Biotech (NASDAQ: PBYI) reported Q3 EPS of $0.46, $0.13 better than the analyst estimate of $0.33. Revenue for the quarter came in at $80.5 million versus the consensus estimate of $70.65 million.
For earnings history and earnings-related data on Puma Biotech (PBYI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Scotiabank Names Top Utility Stocks Amid Data Center Growth
- Spotify (SPOT) PT Raised to $625 at Raymond James
- Freedom Broker Reiterates Buy Rating on Meta Platforms Inc. (META)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
